Compare MCR & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCR | RPID |
|---|---|---|
| Founded | 1989 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.2M | 204.3M |
| IPO Year | N/A | 2021 |
| Metric | MCR | RPID |
|---|---|---|
| Price | $6.00 | $2.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 99.5K | ★ 276.8K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | ★ $33,587,000.00 |
| Revenue This Year | N/A | $19.12 |
| Revenue Next Year | N/A | $18.42 |
| P/E Ratio | $15.68 | ★ N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $5.81 | $1.86 |
| 52 Week High | $6.57 | $4.94 |
| Indicator | MCR | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 31.32 |
| Support Level | $5.84 | $2.01 |
| Resistance Level | $6.39 | $4.48 |
| Average True Range (ATR) | 0.10 | 0.22 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 57.69 | 17.02 |
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.